Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.
- Onco-Innovations is advancing a new class of DNA Damage Response (“DDR”) therapies through the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors designed to disrupt cancer cells’ ability to repair DNA damage.
- The company recently achieved a key manufacturing milestone with the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010.
- A newly signed Letter of Intent with Nanosoft Polymers is expected to support polymer development, drug delivery optimization and formulation work for the ONC010 program.
Cancers frequently exhibit defective repair of damaged DNA, leading to the accumulation of mutations that can give rise to unchecked growth, evasion of the immune system, and the capacity to spread. Conventional DNA damaging therapies, like radiation treatment or some chemotherapies, can overwhelm a cancer’s limited repair capacity resulting in cancer cell death. However, some cancers retain sufficient DNA repair capacity to resist these treatments at doses patients can tolerate.
As researchers continue searching for new ways to overcome that resistance, increasing attention is being directed toward DNA Damage Response inhibitors, an emerging field focused on disabling the repair mechanisms that cancer cells rely on to survive. Such treatments can enhance the effects of DNA damaging therapies, overcoming resistance.
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within this rapidly evolving area of oncology through the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors. PNKP plays a critical role in repairing damaged DNA, and the company’s lead drug candidate, ONC010, is designed to interfere with that process, potentially causing DNA damage to accumulate within cancer cells while enhancing treatment effectiveness.
Beyond its therapeutic pipeline, Onco-Innovations is pursuing a dual-platform strategy that combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development and evidence generation. The approach reflects the growing convergence of precision medicine, advanced analytics and targeted therapeutics within modern cancer care.
As ONC010 advances toward future clinical development, the company has continued to make progress on the manufacturing and formulation infrastructure required to support long-term commercialization efforts. Most recently, Onco-Innovations announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in synthesis of its active pharmaceutical ingredient, A83B4C63.
The milestone represents an important step toward establishing the scalable manufacturing processes needed for formulation development, engineering batches, future GMP production and planned clinical studies. The company’s broader development strategy has also continued to advance on multiple fronts. Earlier this year, Onco-Innovations engaged Nucro-Technics to support bioanalytical method development and validation activities for ONC010, helping generate data intended to support future regulatory submissions and clinical planning efforts. According to the company, the achievement further validates the scalability of its manufacturing approach while supporting the development of a reproducible production process for future clinical supply.
In a separate development, Onco-Innovations signed a Letter of Intent with Nanosoft Polymers aimed at advancing polymer and drug delivery development for ONC010. The agreement outlines the parties’ intention to negotiate a definitive services agreement covering polymer process development, analytical characterization and formulation optimization activities.
The company has also begun laying the groundwork for future clinical evaluation. Through a recently announced engagement with Avance Clinical, a leading Australian contract research organization, Onco-Innovations is advancing clinical and regulatory planning activities intended to support the eventual transition of ONC010 into first-in-human studies. To facilitate these efforts, the company has established an Australian subsidiary, creating a regional presence that may support future clinical operations and development initiatives as the program progresses toward human testing.
While the LOI remains non-binding, it highlights the company’s focus on refining the delivery and formulation characteristics of ONC010 as development progresses. Drug delivery systems can play a critical role in the effectiveness of oncology therapies, particularly when seeking to optimize drug stability, targeting capabilities and overall therapeutic performance.
Taken together, these developments illustrate a coordinated effort to advance ONC010 across multiple stages of the drug development process. From manufacturing scale-up and formulation optimization to preclinical testing and clinical readiness initiatives, Onco-Innovations is continuing to build the infrastructure necessary to support future regulatory engagement and first-in-human evaluation of its PNKP inhibitor platform.
With interest in DNA Damage Response therapies continuing to grow across the oncology landscape, Onco-Innovations is working to establish itself within a promising segment of precision medicine. The company’s recent manufacturing and development achievements demonstrate ongoing progress toward bringing its PNKP inhibitor platform closer to the next stage of development.
For more information, visit https://oncoinnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
